Ligand Pharmaceuticals (LGND) Total Liabilities (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Total Liabilities of $534.8 million for Q1 2026, down 1.59% sequentially from $543.4 million in Q4 2025, and up 386.6% YoY from $109.9 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Total Liabilities (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Total Liabilities for 17 years, with the latest figure at $534.8 million in Q1 2026.
- Quarterly Total Liabilities rose 386.6% year-over-year to $534.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $534.8 million (up 386.6% YoY) and the FY2025 annual result came in at $543.4 million, up 388.1% from the prior year.
- Total Liabilities eased to $534.8 million in Q1 2026 per LGND's latest filing, from $543.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $543.4 million in Q4 2025 and troughed at $86.3 million in Q4 2023.
- A 5-year average of $217.0 million and a median of $120.1 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities slumped 65.97% in 2023, then soared 388.1% in 2025.
- Over 5 years, Total Liabilities stood at $165.2 million in 2022, then tumbled by 47.75% to $86.3 million in 2023, then gained by 29.0% to $111.3 million in 2024, then jumped by 388.1% to $543.4 million in 2025, then decreased by 1.59% to $534.8 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $534.8 million, $543.4 million, and $526.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 1.22 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.22 Bn |
| Mar 31, 2026 | 534.78 Mn |
| Dec 31, 2025 | 543.43 Mn |
| Sep 30, 2025 | 526.60 Mn |
| Jun 30, 2025 | 120.08 Mn |
| Mar 31, 2025 | 109.90 Mn |
| Dec 31, 2024 | 111.34 Mn |
| Sep 30, 2024 | 113.69 Mn |
| Jun 30, 2024 | 91.21 Mn |
| Mar 31, 2024 | 107.35 Mn |
| Dec 31, 2023 | 86.30 Mn |
| Sep 30, 2023 | 101.33 Mn |
| Jun 30, 2023 | 93.21 Mn |
| Mar 31, 2023 | 164.76 Mn |
| Dec 31, 2022 | 165.18 Mn |
| Sep 30, 2022 | 234.31 Mn |
| Jun 30, 2022 | 273.92 Mn |
| Mar 31, 2022 | 311.99 Mn |
| Dec 31, 2021 | 476.43 Mn |
| Sep 30, 2021 | 461.59 Mn |